STEP 5: Care after initial treatment and recovery
The term ‘cancer survivor’ describes a person living with cancer, from the point of diagnosis until the end of life. Survivorship care in Australia has traditionally been provided to patients who have completed active treatment and are in the post-treatment phase. But there is now a shift to provide survivorship care and services from the point of diagnosis to improve cancer-related outcomes.
Cancer survivors may experience inferior quality of life and cancer-related symptoms for up to five years after their diagnosis (Jefford et al. 2017). Distress, fear of cancer recurrence, fatigue, obesity and sedentary lifestyle are common symptoms reported by cancer survivors (Vardy et al. 2019).
Due to an ageing population and improvements in treatments and supportive care, the number of people surviving cancer is increasing. International research shows there is an important need
to focus on helping cancer survivors cope with life beyond their acute treatment. Cancer survivors often face issues that are different from those experienced during active treatment for cancer and may include a range issues, as well as unmet needs that affect their quality of life (Lisy et al. 2019; Tan et al. 2019).
Physical, emotional and psychological issues include fear of cancer recurrence, cancer-related fatigue, pain, distress, anxiety, depression, cognitive changes and sleep issues (Lisy et al. 2019). Late effects may occur months or years later and depend on the type of cancer treatment. Survivors and their carers may experience impacted relationships and practical issues including difficulties with return to work or study and financial hardship. They may also experience changes to sex and intimacy. Fertility, contraception and pregnancy care after treatment may require specialist input.
The Institute of Medicine, in its report From cancer patient to cancer survivor: Lost in transition, describes the essential components of survivorship care listed in the paragraph above, including interventions and surveillance mechanisms to manage the issues a cancer survivor may face (Hewitt et al. 2006). Access to a range of health professions may be required including physiotherapy, occupational therapy, social work, dietetics, clinical psychology, fertility and palliative care. Coordinating care between all providers is essential to ensure the patient’s needs are met.
Cancer survivors are more likely than the general population to have and/or develop comorbidities (Vijayvergia & Denlinger 2015). Health professionals should support survivors to self-manage their own health needs and to make informed decisions about lifestyle behaviours that promote wellness and improve their quality of life (Australian Cancer Survivorship Centre 2010; Cancer Australia 2017; NCSI 2015).
The transition from active treatment to post-treatment care is critical to long-term health. In CLL, this transition is clearer for patients who received time-limited therapy. For patients who received continuous and ongoing therapies, the transitions can be indistinct, but these principles may still apply once disease is well controlled and a stable treatment program is established. In some cases, people will need ongoing, hospital-based care, and in other cases a shared follow-up care arrangement with their general practitioner may be appropriate. This will vary depending on the type and stage of cancer and needs to be planned. Shared follow-up care involves the joint participation of specialists and general practitioners in the planned delivery of follow-up and survivorship care. A shared care plan is developed that outlines the responsibilities of members of the care team, the follow-up schedule, triggers for review, plans for rapid access into each setting and agreement regarding format, frequency and triggers for communication. After completing initial treatment, a designated member of the multidisciplinary team (most commonly nursing or medical staff involved in the patient’s care) should provide the patient with a needs assessment and treatment summary and develop a survivorship care plan in conjunction with the patient. This should include a comprehensive list of issues identified by all members of the multidisciplinary team involved in the patient’s care and by the patient. These documents are key resources for the patient and their healthcare providers and can be used to improve communication and care coordination. The treatment summary should cover, but is not limited to: Given the chronic and often incurable nature of CLL, as well as the frequent use of continuous therapies, long-term management is recommended to retain strong engagement with the primary managing specialist. Even when continuous therapies are used, ongoing monitoring is important to ensure optimal general health. The nature of CLL, along with the cumulative physical and psychological effects of prolonged or repeated phases of treatment, pose substantial psychological burdens on patients, their families and carers. This should be a focus throughout all phases of care. Responsibility for follow-up care should be agreed between the lead clinician, the general practitioner, relevant members of the multidisciplinary team and the patient. This is based on guideline recommendations for post-treatment care, as well as the patient’s current and anticipated physical and emotional needs and preferences. Signs and symptoms of recurrent or progressive CLL such as lymphadenopathy, increasing fatigue, fevers, sweats or unintentional weight loss, and recurrent infections are usually recognised by the patient and reported at routine reviews. After completing time-limited treatment patients should be reviewed at three- to six-monthly intervals in the first few years. These principles also apply to those patients with controlled disease who are receiving continuous therapies. At each visit: Routine surveillance imaging is not recommended and rarely identifies an otherwise unrecognised manifestation of disease recurrence and provides no long-term survival benefit for the patient. Evidence comparing shared follow-up care and specialised care indicates equivalence in outcomes including recurrence rate, cancer survival and quality of life (Cancer Research in Primary Care 2016). Ongoing communication between healthcare providers involved in care and a clear understanding of roles and responsibilities is key to effective survivorship care. In particular circumstances, other models of post-treatment care can be safely and effectively provided such as nurse-led models of care (Monterosso et al. 2019). Other models of post-treatment care can be provided in these locations or by these health professionals: A designated member of the team should document the agreed survivorship care plan. The survivorship care plan should support wellness and have a strong emphasis on healthy lifestyle changes such as a balanced diet, a non-sedentary lifestyle, weight management and a mix of aerobic and resistance exercise (COSA 2018; Hayes et al. 2019). This survivorship care plan should also cover, but is not limited to: Survivors generally need regular follow-up, often indefinitely after cancer treatment finishes. The survivorship care plan therefore may need to be updated to reflect changes in the patient’s clinical and psychosocial status and needs. Processes for rapid re-entry to hospital care should be documented and communicated to the patient and relevant stakeholders. Care in the post-treatment phase is driven by predicted risks (e.g. the risk of recurrence, developing late effects of treatment and psychological issues) as well as individual clinical and supportive care needs. It is important that post-treatment care is based on evidence and is consistent with guidelines. Not all people will require ongoing tests or clinical review and may be discharged to general practice follow-up. The lead clinician should discuss (and general practitioner reinforce) options for follow-up at the start and end of treatment. It is critical for optimal aftercare that the designated member of the treatment team educates the patient about the symptoms of recurrence. General practitioners (including nurses) can: More information Templates and other resources to help with developing treatment summaries and survivorship care plans are available from these organisations: People frequently ask if there is anything else they can do to reduce the risk of CLL recurrence. Not smoking, eating a healthy diet, being sun smart, avoiding or limiting alcohol intake, being physically active and maintaining a healthy body weight may help reduce the risk of a second primary cancer. However, none of these factors have been shown to affect the risk of CLL recurrence or progression. Encourage and support all cancer survivors to reduce modifiable risk factors for other cancers and chronic diseases. Ongoing coordination of care between providers should also deal with any comorbidities, particularly ongoing complex and life-threatening comorbid conditions. Support cancer survivors to participate in research or clinical trials where they are available and appropriate. These might include studies to understand survivors’ issues, to better manage treatment side effects, improve long-term immune function or to improve models of care and quality of life. For more information visit: See validated screening tools mentioned in Principle 4 ‘Supportive care’. Additionally, the ‘Cancer Survivors Unmet Needs (CaSun)’ is another validated screening tool that may help health professionals to identify the unmet needs of patients during survivorship. A number of specific challenges and needs may arise for cancer survivors: Even in long-term disease remission, whether on continuous therapy or after completing time- limited therapy, patients with CLL may have prolonged immune compromise, risk of developing hypogammaglobulinemia, and greatly increased risk of both melanoma and non-melanoma skin cancers. UV precautions and regular skin checks are recommended. It is also important to ensure patients stay up to date with recommended vaccinations including annual seasonal influenza and five-yearly pneumococcal vaccinations. While patients are at continuing risk of herpes zoster reactivation, they are also immunocompromised and may not be suitable for zoster vaccination with live attenuated formulations, so inactivated formulations may be preferred, if available. Specialist infectious diseases guidance may be appropriate (Schmid et al. 2021). For more information on supportive care and needs that may arise for different population groups, see Appendices A, B and C. Rehabilitation may be required at any point of the care pathway from the pre-treatment phase through to disease-free survival and palliative care (Cormie et al. 2017). Issues that may need to be dealt with include managing cancer-related fatigue, coping with cognitive changes, improving physical endurance, achieving independence in daily tasks, returning to study or work and ongoing adjustment to cancer and its consequences. Exercise is a safe and effective intervention that improves the physical and emotional health and wellbeing of cancer patients. Exercise should be embedded as part of standard practice in cancer care and be viewed as an adjunct therapy that helps counteract the adverse effects of cancer and its treatment. Cancer survivors may find referral to specific cancer rehabilitation, optimisation programs or community- based rehabilitation appropriate and beneficial. Other options include referral to allied health supports through team care arrangements and mental health plans. Some community support organisations (cancer-related non-government, not-for-profit and charities) provide services to cancer survivors. The lead clinician (themselves or by delegation) should take responsibility for these tasks: The lead clinician should ensure regular, timely, two-way communication with the general practitioner about: More information Refer to Principle 6 ‘Communication’ for communication skills training programs and resources.